OncoMed Pharmaceuticals Announces Closing of Public

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OncoMed Pharmaceuticals Announces Closing of Public Offering Including Exercise of Underwriters' Right to Purchase Additional Shares

REDWOOD CITY, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED ), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a public offering price of $10.00 per share, which includes the exercise in full of the underwriters' right to purchase up to an additional 825,000 shares of common stock. All shares in the offering were sold by OncoMed, with gross proceeds to OncoMed of approximately $63.3 million and net proceeds of approximately $59.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Leerink Partners LLC acted as sole book-running manager for the offering.  Wells Fargo Securities, LLC and JMP Securities LLC acted as co-managers.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on July 22, 2015. The offering was made only by means of a prospectus supplement. A copy of the final prospectus supplement relating to the offering may be obtained by contacting Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37 th  Floor, Boston, MA, 02110, by email at  syndicate@leerink.com , or by telephone at (800) 808-7525, ext. 6142.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About OncoMed Pharmaceuticals OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics.  OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR.  OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).

Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including OncoMed’s future development plans for its product candidates and the timing thereof. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in research and the clinical development process. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed’s business in general, please refer to OncoMed’s final prospectus supplement filed with the Securities and Exchange Commission (SEC) on August 19, 2016, including the documents incorporated by reference therein, which include OncoMed’s Annual Report on Form 10-K filed with the SEC on March 10, 2016, OncoMed’s Quarterly Report on Form 10-Q filed with the SEC on August 9, 2016, and OncoMed’s other periodic reports filed with the SEC.

Contact: Michelle Corral Senior Director, Investor Relations and Corporate Communications OncoMed Pharmaceuticals michelle.corral@oncomed.com (650) 995-8373

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 460

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 261

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 443

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 448

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 191

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 348

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 430

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 280

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Comparison of Amazon.com with Leading Retail Industry Peers

Updated Category News Views 395

Understanding Amazon.com in the Retail Market In an ever-evolving business environment, investors must carefully analyze leading companies. This article presents a detailed evaluation of Amazon.com Inc (NASDAQ: AMZN) and its position compared to competitors in the Broadline Retail industry. By investigating vital financial metrics and market dynamics, we aim to offer...

Continue Reading
Legal Triumph Brings Significant Gains for Safe & Green Holdings

Updated Category News Views 156

Significant Legal Victory for Safe & Green Holdings Safe & Green Holdings Corp. (NASDAQ: SGBX), a prominent player in the modular building sector, recently celebrated a notable victory in a legal battle that promises to deliver substantial value to its shareholders. The company secured a favorable judgment against EDI International, PC, and PVE, LLC, in a case overseen by...

Continue Reading
Innovative Risk Measure for Joint Replacement Surgeons

Updated Category News Views 107

New Risk-Adjusted Measure for Orthopaedic Surgery The American Joint Replacement Registry (AJRR) has announced the launch of an innovative risk-adjusted revision rate measure designed to support orthopaedic surgeons in evaluating their outcomes. This measure is now available through the RegistryInsights platform and aims to provide more equitable and valuable feedback...

Continue Reading
Bybit's Innovative Indices Trading Enhances Investor Opportunities

Updated Category News Views 77

Bybit Expands Trading Options for Cryptocurrency Investors Bybit, recognized among the leading cryptocurrency exchanges worldwide, has recently enhanced its MetaTrader 5 (MT5) platform by introducing the capability to trade global indices using USDT. This significant feature offers users a unique opportunity to engage with traditional markets while still functioning...

Continue Reading
Shoe Palace Enhances Growth and Efficiency with Centric PLM

Updated Category News Views 303

Shoe Palace Enhances Growth and Efficiency with Centric PLM Centric PLM centralizes product development, providing a single, actionable source of truth for retailers striving for innovation. Shoe Palace, a respected name in footwear and fashion retail, has taken a significant step forward by adopting Centric Product Lifecycle Management (PLM) software. This transition...

Continue Reading